Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
1-Epiandrosterone (3β compound) is covered by S1.1 of the effective 2026 WADA List and is prohibited in and out of competition. S1.1 applies to exogenous administration; its coverage is not limited to the named examples and includes relevant esters. [4]
S1.1; 2026 List, printed pages 5–6 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Identity and human evidence
A seized product labeled “1-Androsterone” was chemically identified as the 3-beta-hydroxy compound corresponding to 1-epiandrosterone, not the distinct 3-alpha compound. A separate four-week randomized study in 17 resistance-trained men reported lean-mass and strength gains alongside adverse lipid and laboratory changes. [1] [2]
- Marketing names are not reliable chemical identifiers. The small trial and biomarkers do not establish organ-disease incidence or a favorable benefit-risk balance.
List year
The 2026 List is the effective edition on this review date. The checked 2027 S1 text showed no change, but the 2027 edition does not take effect until 1 January 2027. [4] [5] [3]
- Consult the official edition and responsible anti-doping organization for consequential decisions. This reference does not provide medical advice, a TUE decision, product certification or individual clearance.
What remains uncertain
- This is a targeted source check, not a systematic review or independent clinical/regulatory sign-off. Uncited draft claims remain unpublished.
- Chemical registry identifiers, every alias and jurisdiction-specific product availability have not been exhaustively reconciled.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- Seized designer supplement named "1-Androsterone": identification as 3β-hydroxy-5α-androst-1-en-17-one and its urinary elimination. ↗Accessed 2026-11-10 · indexed original abstract read via Europe PMC MED record; full article not reviewed
Abstract; PMID 21310167
- Prohormone supplement 3β-hydroxy-5α-androst-1-en-17-one enhances resistance training gains but impairs user health. ↗Accessed 2026-11-10 · indexed original abstract read via Europe PMC MED record; full article not reviewed
Abstract; PMID 24381122
- 2027 Prohibited List resource page ↗Accessed 2026-11-10 · relevant primary-source text read · FUTURE 2027 SOURCE
Resource description and effective date
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · relevant primary-source text read
Introduction and S1, printed pages 3, 5–6
- WADA 2027 Prohibited List, currently linked English file ↗Accessed 2026-11-10 · relevant primary-source text read · FUTURE 2027 SOURCE
Cover and S1, printed pages 1, 5–6
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.